Literature DB >> 21324421

2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

L Samuel Wann, Anne B Curtis, Kenneth A Ellenbogen, N A Mark Estes, Michael D Ezekowitz, Warren M Jackman, Craig T January, James E Lowe, Richard L Page, David J Slotwiner, William G Stevenson, Cynthia M Tracy, Valentin Fuster, Lars E Rydén, David S Cannom, Harry J Crijns, Anne B Curtis, Kenneth A Ellenbogen, Jonathan L Halperin, G Neal Kay, Jean-Yves Le Heuzey, James E Lowe, S Bertil Olsson, Eric N Prystowsky, Juan Luis Tamargo, L Samuel Wann, Alice K Jacobs, Jeffrey L Anderson, Nancy Albert, Mark A Creager, Steven M Ettinger, Robert A Guyton, Jonathan L Halperin, Judith S Hochman, Frederick G Kushner, Erik Magnus Ohman, William G Stevenson, Clyde W Yancy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21324421     DOI： 10.1016/j.hrthm.2011.01.032

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN： 1547-5271            Impact factor:   6.343


× No keyword cloud information.
  6 in total

1.  Dabigatran etixilate and traumatic brain injury: Evolving anticoagulants require evolving care plans.

Authors:  Sam Pakraftar; Daniela Atencio; John English; Alain Corcos; Eric M Altschuler; Kurt Stahlfeld
Journal:  World J Clin Cases       Date:  2014-08-16       Impact factor: 1.337

2.  Recent Atrial Fibrillation Guidelines - Looking at Both Sides of the Atlantic.

Authors:  Samuel Lévy
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-04

3.  Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation.

Authors:  Soyon Lee; Rachel Mullin; Jon Blazawski; Craig I Coleman
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

4.  Trends in the use of echocardiography in pulmonary embolism.

Authors:  Brijesh Patel; Mahek Shah; Lohit Garg; Manyoo Agarwal; Matthew Martinez; Raman Dusaj
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

5.  Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database.

Authors:  Sally Lee; Brigitta U Monz; Andreas Clemens; Martina Brueckmann; Gregory Y H Lip
Journal:  BMJ Open       Date:  2012-12-14       Impact factor: 2.692

6.  A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.

Authors:  Sonja V Sorensen; Siyang Peng; Brigitta U Monz; Carole Bradley-Kennedy; Anuraag R Kansal
Journal:  Pharmacoeconomics       Date:  2013-07       Impact factor: 4.981
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.